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Abstract
Mutations in CHCHD10 have recently been described as a cause of frontotemporal dementia 
(FTD) co-morbid with amyotrophic lateral sclerosis (ALS). The aim of this study was to assess the 
frequency and clinical characteristics of CHCHD10 mutations in Italian patients diagnosed with 
familial (n = 64) and apparently sporadic ALS (n = 224). Three apparently sporadic patients were 
found to carry c.100C>T (p.Pro34Ser) heterozygous variant in the exon 2 of CHCHD10. This 
mutation had been previously described in two unrelated French patients with FTD-ALS. 
However, our patients had a typical ALS, without evidence of FTD, cerebellar or extrapyramidal 
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signs, or sensorineural deficits. We confirm that CHCHD10 mutations account for ∼1% of Italian 
ALS patients and are a cause of disease in subject without dementia or other atypical clinical 
signs.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder 
affecting motor neurons and clinically characterized by paralysis and respiratory failure 
leading to death, typically within 3 to 5 years of symptom onset. Approximately 10% of 
patients have a family history for ALS or frontotemporal dementia (FTD). The genetic 
etiology of two thirds of these cases has been identified, with mutations in SOD1, TARDBP 
and FUS, as well as the pathogenic repeat expansion in C9ORF72, being the most common 
causes (Chiò et al, 2013; Renton et al, 2014).
Recently, a missense mutation in the coiled-coil-helix-coiled-coil-helix domain containing 
10 (CHCHD10) gene on chromosome 22q.11.23 was reported to cause FTD-ALS in a large 
French pedigree (Banwarth et al, 2014). Additional mutations were subsequently reported in 
ALS pedigrees without cognitive impairment (Müller et al, 2014; Johnson et al, 2014). 
However, the importance of CHCHD10 mutations as a cause of ALS remains unclear. The 
aim of the current study is to determine the frequency of CHCHD10 mutations in a cohort of 
familial (fALS) and sporadic (sALS) Italian ALS patients.
2. Methods
2.1 Samples
Samples includes (a) 64 unrelated Italian probands with familial ALS (fALS) recruited 
through the Italian ALS Genetic (ITALSGEN) consortium; (b) 224 apparently sporadic 
Italian ALS cases (sALS) diagnosed between June 2012 and June 2014 and residing in 
Piemonte. These cases were identified through the Piemonte and Valle d'Aosta registry for 
ALS (PARALS) (Chio et al, 2012); and (c) 165 healthy Italian controls that were age- and 
gender-matched to patients. These individuals were recruited using the list of the patients 
attending the same general practitioners as the sporadic ALS patients. ALS cases were 
negative for mutations in SOD1, TARDBP and FUS, and did not carry the C9ORF72 
pathogenic repeat expansion.
Patients with definite, probable, probable-laboratory supported or possible ALS were 
included in the analysis (Brooks et al, 2000). All cases were tested for cognitive impairment 
using an extensive test battery (listed in Appendix) (Strong et al, 2009; Montuschi et al, 
2014).
2.2 Sequencing of CHCHD10
Coding exons and flanking intronic regions of CHCHD10 (NM_213720.2) were amplified 
by PCR and analyzed by DHPLC (Transgenomic, Inc., Omaha, NE, USA). PCR products 
with abnormal heteroduplex profiles were sequenced on an ABI 3130 sequencer (Life 
Technologies, Foster City, CA, USA). Primer sequences and PCR conditions are listed in 
the Appendix.
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2.3 Standard Protocol Approvals and Patient Consents
The ethical committees of the recruiting centers approved the study. All patients and control 
subjects proved written informed consent. Databases were treated according to the Italian 
regulations for privacy.
3. Results
Demographic and clinical characteristics of the ALS patients and controls are reported in 
Table 1. In our screening of the 288 ALS patients, we found seven cases carrying four 
distinct variants in CHCHD10 (Table 2). Of these, a c.100C>T heterozygous variant in the 
exon 2 leading to the substitution of a serine for a proline residue (p.Pro34Ser) was found in 
three apparently sporadic ALS cases. This mutation was not present in online databases of 
human polymorphisms including dbSNP (build 138), the 1000 Genomes database (phase 3 
release), and the 60,706 cases of the Exome Aggregation Consortium (ExAC, 
exac.broadinstitute.org). In silico analysis (polyphen) predicted that this amino acid change 
was damaging to protein function.
Other genetic variants identified in CHCHD10 in our Italian cohort were: c.234G>A 
(p.Ser78Ser), c.274G>A (p.Ala92Thr), c.286C>A (p.Pro96Thr), and c.312C>T 
(P.Tyr104Tyr). There variants were of unclear pathogenicity as they were also present in 
Italian controls, online databases of human polymorphisms, or were predicted to result in 
benign changes by in silico analysis.
3.1 Clinical description of patients carrying p.Pro34Ser CHCHD10 mutation
The first patient was a 69-year-old woman who presented with dysarthria and dysphagia. 
Neurological examination performed six months after symptom onset found tongue atrophy 
with a positive jaw jerk, atrophy and weakness of the small muscles of the hand, and 
generalized hyperreflexia. Neurophysiological examination showed diffuse signs of active 
and chronic denervation. Neuropsychological testing was normal. Familial history was 
negative for ALS or FTD: her father died at age 57 from lung cancer and her mother at 61 
due to breast cancer. Her two siblings were negative for neurological disorders. She died 
from respiratory failure 18 months after symptom onset.
The second patient developed weakness of his right shoulder at 58 years of age. 
Neurological examination revealed marked atrophy and weakness of both shoulder girdles 
(more marked on the right side). Deep tendon reflexes were normal in the upper limbs and 
hyperreflexic in lower limbs. Babinski and Hoffman signs were not present. Cervical MRI 
was normal and neurophysiological examination demonstrated chronic denervation of 
cervical region. He was cognitively normal. Family history was negative for ALS. However, 
his 94 years old mother was alive and affected by progressive gait impairment of unclear 
etiology.
The third patient was a 44-year-old woman who presented with dysarthria. Neurological 
examinations performed three months after symptom onset revealed, tongue atrophy and 
fasciculations, weakness and hypotrophy of small hand muscles, and generalized 
hyperreflexia. Neurophysiological testing showed diffuse signs of active and chronic 
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denervation. Neuropsychological examination was normal. Familial history was negative for 
ALS or FTD: her father died at 72 years of age due to cirrhosis and her mother died at 56 
due to cerebral hemorrhage. Her six siblings were negative for neurological disorders. She 
died from respiratory failure fifteen months after symptom onset.
4. Discussion
We have found that ∼1% of our Italian series of ALS patients carried the p.Pro34Ser 
mutation of CHCHD10. This mutation has been already described in two unrelated French 
patients with FTD-ALS (Chaussenot et al, 2014). However, in contrast to the previously 
reported patients, our cases manifested classic ALS, and all three patients were cognitively 
normal without cerebellar, extrapyramidal signs or sensorineural deficits. Nevertheless, the 
clinical picture of our patients was heterogeneous: two patients manifested rapid clinical 
deterioration whereas the third case had a relatively mild course; two of patients had a 
predominantly bulbar phenotype, similar to the original pedigree (Bannwarth et al, 2014), 
whereas the third patient presented with limb-onset disease.
Our findings are consistent with previous reports. The first patients carrying mutations of 
this gene had a pure FTD or FTD-ALS phenotype (Bannwarth et al, 2014; Chaussenot et al, 
2014). More recently, two missense mutations in the CHCHD10 gene have been reported in 
patients with pure ALS, confirming that mutations of this gene can be associated with 
typical familial ALS without cognitive involvement and account for 1 to 2% of fALS.
To date, pathogenetic mutations of the CHCHD10 gene are concentrated in exon 2, which 
encodes the non-structured N-terminal region and a highly hydrophobic helix (Gly43 to Ala 
68) that may act as an interface with another protein (Chaussenot et al, 2014). CHCHD10 
protein activity is related to mitochondrial function, most notably the maintenance of 
mitochondrial integrity, and this may represent an interesting target for future therapeutic 
development.
Our data provide strong support for the pathogenicity of CHCHD10 in ALS, broadens the 
phenotype associated with mutations in this gene, and suggests that certain mutations are 
associated with reduced penetrance. The relatively high frequency of CHCHD10 mutations 
in our series indicated that it should be screened both in fALS and in apparently sALS 
patients.
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Appendix. Primer sequences and PCR conditions
Primers
CHCHD10 Exon 1Fnew GGAGAAGGGGGATAGGGTTG
CHCHD10 Exon 1Rnew agcagcagccaaggtcactc
CHCHD10 Exon 2F CTCCTCACTGGACACTTGGG
CHCHD10 Exon 2R GGTCGTTTCCAGGAGCTG
CHCHD10 Exon 3Fnew aggtggccccaggtttgaa
CHCHD10 Exon 3Rnew aggtgcaagaggagggttgg
CHCHD10 Exon 4F ACCTCATCAGCCAGGGAG
CHCHD10 Exon 4R CCAACCCTCCTCTTGCAC
PCR conditions
PCR MIX Exons 1-3-4 (1ul DNA, 10 ng/ul)
2× Roche Master Mix 12.5 ul
50μM Forward Primer 0.2 ul
50μM Reverse Primer 0.2 ul
N/A H2O 11.1 ul
PCR MIX for exon2 (1ul DNA, 10 ng/ul)
2× Roche Master Mix 12.5 ul
50μM Forward Primer 0.2 ul
50μM Reverse Primer 0.2 ul
Betaine (5M) 5 ul
N/A H2O 6.1 ul
Amplification of exons 1,3,4 was performed using Roche Master mix in a touch-down PCR 
protocol with an initial denaturation at 94°C for 4 min, followed by 25 cycles of 
denaturation at 94°C for 30 sec, annealing at 65°C In the first cycle with 1.0°C decremental 
in each subsequent cycle for 30 sec, and elongation at 72°C for 45 sec. This was followed by 
20 cycles at 94°C for 30sec, 55°C for 30 sec, and 72°C for 45 sec, with a final step at 72°C 
for 15 min. To enhance the formation of heteroduplex for DHPLC analysis, samples were 
denaturated at 95°C for 1 min, and then slowly cooled for 30 cycles at rate of 1°C/cycle.
For the exon2 the touch-down protocol was modified using 20 cycles with annealing at 66°C 
and decremental of 0.5°C/cycle followed by 25 cycles at annealing at 56°C; chemical 
conditions for amplification were adjusted by adding betaine in the standard protocol, as 
listed in table below.
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This is the first paper reporting the new discovered gene CHCHD10 in a large series of 
Italian familial and sporadic ALS patients. It demonstrates the mutation of this gene can 
be detected in apparently sporadic ALS patients with a ‘typical’ clinical picture, i.e. 
without dementia or cerebellar signs.
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Table 1
Demographic and clinical characteristics of cases and controls
fALS n=64 sALS n=224 Controls n=165
Age at onset 58.3 (10.4) 65.9 (11.4) 65.1 (10.1)
Gender (women, %) 18 (28.1%) 101 (45.1%) 73 (44.2%)
Site of onset (bulbar, %) 21 (32.8%) 68 (30.3%) -
FTD 10 (15.7%) 31 (14.8%) -
sALS, sporadic ALS; fALS, familial ALS; FTD, frontotemporal dementia
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